# IMP4297 DDI (Drug-Drug Interaction)Trial in Healthy Male Volunteers

> **NCT04584515** · PHASE1 · COMPLETED · sponsor: **Impact Therapeutics, Inc.** · enrollment: 32 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** IMP4297 40 mg
- **DRUG:** IMP4297 100 mg

## Key facts

- **NCT ID:** NCT04584515
- **Lead sponsor:** Impact Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-02
- **Primary completion:** 2021-03-08
- **Final completion:** 2021-05-27
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2021-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04584515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04584515, "IMP4297 DDI (Drug-Drug Interaction)Trial in Healthy Male Volunteers". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04584515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*